<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">20046575</PMID>
        <DateCompleted>
            <Year>2010</Year>
            <Month>04</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1942-0870</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <MedlineDate>2009 Jan-Feb</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>mAbs</Title>
                <ISOAbbreviation>MAbs</ISOAbbreviation>
            </Journal>
            <ArticleTitle>New challenges to medicare beneficiary access to mAbs.</ArticleTitle>
            <Pagination>
                <MedlinePgn>56-66</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Precision binding of monoclonal antibodies (mAbs) to biological targets, their relative clinical success, and expansion of indications following initial approval, are distinctive clinical features. The relatively high cost of mAbs, together with the absence of a regulatory pathway to generics, stand out as distinctive economic features. Based on both literature review and primary data collection we enumerated mAb original approvals, supplemental indications and off-label uses, assessed payer formulary management of mAbs, and determined new challenges to Medicare beneficiary access to mAbs. We found that the FDA has approved 22 mAbs and 30 supplemental indications pertaining to the originally approved mAbs. In addition, there are 46 off-label use citations in officially recognized pharmaceutical compendia. Across Part B carriers and Part D plans, we found considerable variation in terms of coverage and conditions of reimbursement related to on- and off-label uses of mAbs. Our results point to four major challenges facing mAb developers, health care providers, Medicare beneficiaries, payers and policymakers. These include administrative price controls, coverage variation, projected shift from physician- to self-administered mAbs, and comparative effectiveness. We suggest more systematic use of &quot;coverage with evidence development&quot; as a means of optimally addressing these challenges.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>Joshua</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tufts Center for the Study of Drug Development (CSDD), Boston, Massachusetts 02111, USA. joshua.cohen@tufts.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilson</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>MAbs</MedlineTA>
            <NlmUniqueID>101479829</NlmUniqueID>
            <ISSNLinking>1942-0862</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>MAbs. 2009 Jan-Feb;1(1):29-30</RefSource>
                <PMID Version="1">20046571</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D033161" MajorTopicYN="N">Government Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056687" MajorTopicYN="N">Off-Label Use</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011050" MajorTopicYN="N">Policy Making</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>40</NumberOfReferences>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">comparative effectiveness</Keyword>
            <Keyword MajorTopicYN="N">formulary management</Keyword>
            <Keyword MajorTopicYN="N">mAbs</Keyword>
            <Keyword MajorTopicYN="N">medicare</Keyword>
            <Keyword MajorTopicYN="N">off-label</Keyword>
            <Keyword MajorTopicYN="N">reimbursement</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>09</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>10</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>4</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">20046575</ArticleId>
            <ArticleId IdType="pmc">PMC2715185</ArticleId>
            <ArticleId IdType="doi">10.4161/mabs.1.1.7246</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Health Aff (Millwood). 2006 Sep-Oct;25(5):1319-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16966729</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Aff (Millwood). 2006 Sep-Oct;25(5):1260-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16966721</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BioDrugs. 2007;21(1):1-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17263584</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2007 May;6(5):349-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17431406</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Biotechnol. 2007 Oct;25(10):1097-104</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17921989</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Technol Assess Health Care. 2007 Fall;23(4):425-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17937829</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Fed Regist. 2007 Nov 27;72(227):66579-7226</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18044033</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2007 Dec 27;357(26):2666-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18160686</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Aff (Millwood). 2008 Jan-Feb;27(1):w34-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18042561</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Discov Today. 2008 Jan;13(1-2):30-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18190861</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Biotechnol. 2008 Feb;26(2):151-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18259163</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Biotechnol. 2008 Aug;26(8):867-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18688236</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Health Serv Res Policy. 2003 Jul;8(3):183-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12869346</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Manag Care Pharm. 2004 May;10(3 Suppl):S4-9; quiz S19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15228370</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Manag Care Pharm. 2004 May;10(3 Suppl):S10-6; quiz S20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15228371</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Aff (Millwood). 2005 Jul-Aug;24(4):938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16012136</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Aff (Millwood). 2005 Jul-Aug;24(4):1117-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16012152</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Aff (Millwood). 2006 Sep-Oct;25(5):1231-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16966718</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
